RxDoctor Payments Data

Kathia Ortiz-Cantillo, MD

Critical Care Medicine · Savannah, GANPI 1841301140

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,308 of the $7,526 with a category attached, or 70.5%. 27 manufacturers reported payments, led by Olympus Corporation Of The Americas at 26.6% of the total. Among critical care medicine clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,526in general payments, 2019–2025

Across 274 payments — averaging $27.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus Corporation Of The Americas$2K
  • AstraZeneca$931
  • GSK$727
  • Insmed, Inc.$487
  • Boehringer Ingelheim$484
  • Electromed, Inc.$461
  • plus $2K from 21 others

What the payments were for

  • Travel & lodging$1,85725%
  • Food & beverage$5,30871%
  • Education$3625%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,526 in reported general payments places this provider in the 90th percentile of 265 critical care medicine providers in Georgia.

See all critical care medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$257,102
Medicare patients
637
Services billed
1,547

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate18$314,789
Trelegy ElliptaFluticasone/Umeclidin/Vilanter217$296,127
Breztri AerosphereBudesonide/Glycopyr/Formoterol84$105,513
Prolastin CAlpha-1-Proteinase Inhibitor12$70,583
NucalaMepolizumab12$42,501
Breo ElliptaFluticasone/Vilanterol40$27,960
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr40$27,615
OzempicSemaglutide19$16,277
Spiriva RespimatTiotropium Bromide21$15,172
Arnuity ElliptaFluticasone Furoate32$14,847
Spiriva HandihalerTiotropium Bromide11$14,015
Bevespi AerosphereGlycopyrrolate/Formoterol Fum16$11,591
Fluticasone-SalmeterolFluticasone Propion/Salmeterol45$9,085
Albuterol Sulfate HfaAlbuterol Sulfate173$7,395
Combivent RespimatIpratropium/Albuterol Sulfate11$7,245

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$727$409,051341 claims
Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat$484$337,20750 claims
AstraZenecaBreztri Aerosphere, Bevespi Aerosphere$931$117,104100 claims
Grifols USA, LLCProlastin C$204$70,58312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 265 critical care medicine providers in Georgia.

Other critical care medicine in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →